Rhabdomyolysis Due to Micronized Fenofibrate

Oguzhan N., ÜNAL A., SİPAHİOĞLU M. H., TOKGÖZ B., OYMAK O., Utas C.

ENDOCRINOLOGIST, cilt.20, sa.6, ss.288-289, 2010 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 6
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1097/ten.0b013e3181fd0370
  • Dergi Adı: ENDOCRINOLOGIST
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.288-289
  • Erciyes Üniversitesi Adresli: Evet

Özet

Fenofibrate, a fibric acid derivative, is frequently used to treat diabetic dyslipidemia and hypertriglyceridemia alone or in combination with statins. Rhabdomyolysis is a syndrome that results from striated muscle necrosis and release of its contents into the systemic circulation and extracellular fluid. Fenofibrate-induced rhabdomyolysis is a rare clinical condition if there is not a predisposing factor such as diabetes mellitus, hypothyroidism, and renal insufficiency. In this study, we present a case of a patient who developed rhabdomyolysis after micronized fenofibrate use without known predisposing factor.